BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 9326220)

  • 21. T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.
    Drobyski WR; Hessner MJ; Klein JP; Kabler-Babbitt C; Vesole DH; Margolis DA; Keever-Taylor CA
    Blood; 1999 Jul; 94(2):434-41. PubMed ID: 10397710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.
    Sawyers CL; Timson L; Kawasaki ES; Clark SS; Witte ON; Champlin R
    Proc Natl Acad Sci U S A; 1990 Jan; 87(2):563-7. PubMed ID: 2405384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clonally unrelated BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia.
    Manley R; Cochrane J; McDonald M; Rigby S; Moore A; Kirk A; Clarke S; Crossen PE; Morris CM; Patton WN
    Leukemia; 1999 Jan; 13(1):126-9. PubMed ID: 10049047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation.
    Chomel JC; Brizard F; Veinstein A; Rivet J; Sadoun A; Kitzis A; Guilhot F; Brizard A
    Blood; 2000 Jan; 95(2):404-8. PubMed ID: 10627442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies.
    Niederle N; Kloke O; Wandl UB; Becher R; Moritz T; Opalka B
    Leuk Lymphoma; 1993 Jan; 9(1-2):111-9. PubMed ID: 8477190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha-2b-interferon as single therapy for patients with chronic myeloid leukemia relapsing after T-cell depleted allogeneic bone marrow transplantation.
    Arcese W; Mauro FR; Screnci M; Alimena G; Iori AP; De Cuia MR; Lo Coco F; Montefusco E; Fazi P; Mandelli F
    Eur J Haematol Suppl; 1990; 52():36-9. PubMed ID: 2279545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
    Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
    Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.
    Hochhaus A; Reiter A; Saussele S; Reichert A; Emig M; Kaeda J; Schultheis B; Berger U; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
    Blood; 2000 Jan; 95(1):62-6. PubMed ID: 10607685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What does one do for the CML patient in relapse after allogeneic bone marrow transplantation?
    Arcese W; Iori AP; Di Nucci G; Martinez-Rolon J; Pinto RM; Mandelli F
    Leuk Lymphoma; 1993; 11 Suppl 1():213-9. PubMed ID: 8251899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extramedullary blast crisis in a patient with chronic myelogenous leukemia in complete cytogenetic and molecular remission on interferon-alpha therapy.
    Beedassy A; Topolsky D; Styler M; Crilley P
    Leuk Res; 2000 Aug; 24(8):733-5. PubMed ID: 10936425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.
    Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Heinze B
    Blood; 1994 Dec; 84(12):4064-77. PubMed ID: 7994025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients.
    Radich JP; Gehly G; Gooley T; Bryant E; Clift RA; Collins S; Edmands S; Kirk J; Lee A; Kessler P
    Blood; 1995 May; 85(9):2632-8. PubMed ID: 7727789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon therapy for Ph1 positive CML patients relapsing after T cell-depleted allogeneic bone marrow transplantation.
    Arcese W; Mauro FR; Alimena G; Lo Coco F; De Cuia MR; Screnci M; Iori AP; Montefusco E; Mandelli F
    Bone Marrow Transplant; 1990 May; 5(5):309-15. PubMed ID: 2350627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.
    Delage R; Soiffer RJ; Dear K; Ritz J
    Blood; 1991 Nov; 78(10):2759-67. PubMed ID: 1824268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with recombinant interferon (alpha-2b) early after bone marrow transplantation in patients at high risk for relapse [corrected].
    Klingemann HG; Grigg AP; Wilkie-Boyd K; Barnett MJ; Eaves AC; Reece DE; Shepherd JD; Phillips GL
    Blood; 1991 Dec; 78(12):3306-11. PubMed ID: 1742491
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.
    Opalka B; Wandl UB; Becher R; Kloke O; Nagel-Hiemke M; Moritz T; Beer U; Seeber S; Niederle N
    Blood; 1991 Nov; 78(9):2188-93. PubMed ID: 1932740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
    Lin F; Kirkland MA; van Rhee FV; Chase A; Coulthard S; Bungey J; Goldman JM; Cross NC
    Bone Marrow Transplant; 1996 Dec; 18(6):1147-52. PubMed ID: 8971386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
    Nese M; de Bellis R; Urtiarte R; Di Landro J
    Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.